Pharmacophore-based discovery of ligands for drug transporters.
about
Functional group and substructure searching as a tool in metabolomicsIn silico prediction of inhibition of promiscuous breast cancer resistance protein (BCRP/ABCG2)Fitting the elementary rate constants of the P-gp transporter network in the hMDR1-MDCK confluent cell monolayer using a particle swarm algorithmMembrane transporters in drug developmentUltra-High-Throughput Structure-Based Virtual Screening for Small-Molecule Inhibitors of Protein-Protein Interactions.Pharmacophore modeling of nilotinib as an inhibitor of ATP-binding cassette drug transporters and BCR-ABL kinase using a three-dimensional quantitative structure-activity relationship approachNovel inhibitors of human organic cation/carnitine transporter (hOCTN2) via computational modeling and in vitro testingDiscovery of novel selective serotonin reuptake inhibitors through development of a protein-based pharmacophore.Why we should be vigilant: drug cytotoxicity observed with in vitro transporter inhibition studies.Recent advances in ligand-based drug design: relevance and utility of the conformationally sampled pharmacophore approach.Molecular analysis and structure-activity relationship modeling of the substrate/inhibitor interaction site of plasma membrane monoamine transporter.In silico pharmacology for drug discovery: applications to targets and beyondStructure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP)In vitro models for processes involved in intestinal absorption.Machine learning methods and docking for predicting human pregnane X receptor activation.Future directions for drug transporter modelling.Drug transport across the placenta, role of the ABC drug efflux transporters.SLC Transporters: Structure, Function, and Drug Discovery.Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.Structure-activity relationships and quantitative structure-activity relationships for breast cancer resistance protein (ABCG2).Drug transport by breast cancer resistance protein.New design strategies for antidepressant drugs.The Complexities of Interpreting Reversible Elevated Serum Creatinine Levels in Drug Development: Does a Correlation with Inhibition of Renal Transporters Exist?Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms.Cysteine scanning mutagenesis of transmembrane domain 10 in organic anion transporting polypeptide 1B1Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactionsIn silico Screening and Evaluation of the Anticonvulsant Activity of Docosahexaenoic Acid-Like Molecules in Experimental Models of SeizuresTanshinone IIA increases mRNA expression of efflux transporters in cultured human intestinal cell.A Fragment-Based Scoring Function to Re-rank ATP Docking Results.In Silico ADME/Tox PredictionsIn silicoprediction of substrate properties for ABC-multidrug transportersTransporters in Drug DiscoveryADME
P2860
Q28472062-0D50408B-ED31-43DD-A321-C2D85458BD88Q28540667-A489252C-1530-4558-83A6-C64E6EBDC5BEQ28743796-BE70154E-83F8-4591-937D-673A726C169CQ29616802-E7270272-3728-4E59-8462-F48E655B8DB5Q30383112-0A8C9E47-9F90-4BF3-9EF9-36B24CC77969Q33863299-E692F44D-6B53-491E-B17B-8B81D0A55FDAQ33939558-4B1AC00C-B33E-47B7-9CB2-4D95B0C4DC74Q33990707-AF5A3DE9-ED2D-40F7-A29C-44F7C1806F33Q34148447-36A57630-75D4-454C-8312-0FAB97C1A303Q34288171-0ECDFA97-800D-40E8-8111-93D91C8D835CQ35429797-15EC58FC-4DDE-4C6D-AAD1-9F406DE003C7Q35995265-9FFD8230-9455-40F1-B924-3CC1B2656D86Q36742673-94FFD8EA-1746-4B01-9856-173635C69476Q36909324-27B492B9-5327-42E4-936A-347D567E81E4Q36951921-14C9E8A4-1EF8-4A21-95B9-9E4ACA102BF9Q36985072-613EF1CE-EDB0-4828-AF92-48D19E5A3D5AQ37008886-087EFBA0-1943-416A-9C40-342C6D91C470Q37279747-E4CB2C1F-A2A8-44A5-B71E-CAE025F64A01Q37347179-BAB2FDE1-B005-4504-9F1B-11521EB800A8Q37560771-0C67AADC-6B57-4172-A34A-2D81BC2079CDQ37793056-738720F0-18F1-4062-ACBC-DEF21826B2D4Q38132807-EB6FD551-AFBB-4194-952A-F81239855A4DQ38716267-C35B97EF-30ED-4B87-946F-D4D489D3310DQ38812867-0062BF30-625E-4CF3-A0D3-ABC1891962BBQ39044921-6878CC91-91C8-40B5-AF9B-DF4007F72460Q41172510-95C5C40D-A624-40BD-9859-A212F4F4C6D7Q42826496-ED542312-9085-4122-A723-FD5C9B191320Q42915310-6DDA1F8D-2DB6-4673-99AC-70832E168CECQ45777298-BBD51D90-09A2-4018-B3EC-FFF7792B407DQ56984194-6B390D8A-16FD-4A7F-8F47-359052702C79Q56992289-BB615F4A-8705-41C1-B09D-6EA181DB8D3DQ57684264-14FC2D71-91C1-40F1-96D3-ED7139874852Q57684720-02B6E583-ADDD-4AE5-80BC-44AC3F5F412E
P2860
Pharmacophore-based discovery of ligands for drug transporters.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Pharmacophore-based discovery of ligands for drug transporters.
@ast
Pharmacophore-based discovery of ligands for drug transporters.
@en
type
label
Pharmacophore-based discovery of ligands for drug transporters.
@ast
Pharmacophore-based discovery of ligands for drug transporters.
@en
prefLabel
Pharmacophore-based discovery of ligands for drug transporters.
@ast
Pharmacophore-based discovery of ligands for drug transporters.
@en
P2860
P1476
Pharmacophore-based discovery of ligands for drug transporters.
@en
P2093
Cheng Chang
Praveen Bahadduri
P2860
P304
P356
10.1016/J.ADDR.2006.09.006
P407
P577
2006-09-26T00:00:00Z